Regeneronreason 02 of 4it is wired into how the customer already worksderived 2026-09-08accession 0000872589-26-000025
EYLEA HD was launched in 2023 and entered the highly competitive environment described above
The FDA recently approved EYLEA HD for the treatment of RVO and for additional dosing regimens
no findingread · nothing bore on it
It held on this filing. No finding was written because nothing in it bore on the reason — the sentences it was read against are below.
the evidence · every sentence checkedthree sentences · whole, uncut
the claims it rests on
“EYLEA HD was launched in 2023 and entered the highly competitive environment described above”
“The FDA recently approved EYLEA HD for the treatment of RVO and for additional dosing regimens”
what it was checked against
RVO approval and additional dosing regimens
“While the FDA recently approved EYLEA HD for the treatment of RVO and for additional dosing regimens and we continue to work toward FDA approval of the EYLEA HD pre-filled syringe as discussed under Part I, Item 2.”